Anakinra is a recombinant IL-1 receptor inhibitor commonly used for the treatment of autoinflammatory diseases in rheumatology. Successful off-label use of anakinra has been reported in different cases of severe HS. Several reports, in addition to our case, show that patients’ selection remains important since not all patients with HS respond well to anti-IL1 therapy, and further clinical investigation is needed to help on the predictive response to the different biological treatments
© 2001-2024 Fundación Dialnet · Todos los derechos reservados